Publication | Closed Access

Targeting a marker of the tumour neovasculature using a novel anti-human CD105-immunotoxin containing the non-toxic type 2 ribosome-inactivating protein nigrin b

MedicineImmunologyPathologyImmune Checkpoint InhibitorTumour NeovasculatureNovel Anti-human Cd105-immunotoxinTumor TargetingImmunotherapyOncologyCancer ResearchTumor MicroenvironmentTumor BiologyNon-toxic Type 2